APLT vs. OCS, KALV, FULC, IGMS, KRRO, ANL, TVTX, LRMR, VERV, and ATXS
Should you be buying Applied Therapeutics stock or one of its competitors? The main competitors of Applied Therapeutics include Oculis (OCS), KalVista Pharmaceuticals (KALV), Fulcrum Therapeutics (FULC), IGM Biosciences (IGMS), Korro Bio (KRRO), Adlai Nortye (ANL), Travere Therapeutics (TVTX), Larimar Therapeutics (LRMR), Verve Therapeutics (VERV), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical preparations" industry.
Applied Therapeutics (NASDAQ:APLT) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.
In the previous week, Oculis had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 5 mentions for Oculis and 4 mentions for Applied Therapeutics. Applied Therapeutics' average media sentiment score of 1.35 beat Oculis' score of 0.85 indicating that Applied Therapeutics is being referred to more favorably in the media.
Applied Therapeutics has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500. Comparatively, Oculis has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.
Applied Therapeutics currently has a consensus target price of $11.00, indicating a potential upside of 161.90%. Oculis has a consensus target price of $30.17, indicating a potential upside of 153.50%. Given Applied Therapeutics' higher possible upside, research analysts plainly believe Applied Therapeutics is more favorable than Oculis.
Applied Therapeutics received 53 more outperform votes than Oculis when rated by MarketBeat users. However, 85.71% of users gave Oculis an outperform vote while only 56.35% of users gave Applied Therapeutics an outperform vote.
Applied Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -6,712.02%. Oculis' return on equity of -52.72% beat Applied Therapeutics' return on equity.
Oculis has lower revenue, but higher earnings than Applied Therapeutics. Oculis is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.
98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 8.6% of Applied Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Applied Therapeutics beats Oculis on 9 of the 17 factors compared between the two stocks.
Get Applied Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Applied Therapeutics Competitors List
Related Companies and Tools
